United Therapeutics Corp

NASDAQ: UTHR
$374.29
-$0.11 (0.0%)
Real Time Data Delayed 15 Min.

UTHR Stock Chart and Intraday Price

UTHR Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 1040 SPRING ST, SILVER SPRING, MD, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 10,913.81M USD
Shares Outstanding 47,058,500
United Therapeutics Corporation is a biotechnology firm focused on creating innovative treatments for patients with chronic and life-threatening diseases worldwide. It specializes in therapies for pulmonary arterial hypertension (PAH), offering a range of products including inhaled solutions, tablets, and injections to improve exercise capacity and delay disease progression. Additionally, the company works on high-risk neuroblastoma treatments and is developing new technologies for subcutaneous drug delivery and gene therapy. Founded in 1996 and based in Silver Spring, Maryland, United Therapeutics is also exploring organ xenografts and has several strategic partnerships for product development.

UTHR Articles

Tuesday's top analyst upgrades and downgrades included CrowdStrike, Diamondback Energy, DoorDash, Etsy, JetBlue Airways, Lululemon Athletica, Marriott International and Silvergate Capital.
Tuesday's top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup,...
Tuesday's top analyst upgrades and downgrades included Accenture, Altria, American Airlines, APA, Bumble, Chevron, Datadog, General Motors, Mastercard, Pinduoduo, Regeneron Pharmaceuticals, Tesla,...
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic selling...
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Cree, Etsy, Gilead Sciences, Pfizer, Rite Aid, Solar Edge, Square, 3D Systems and Virgin Galactic.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
The top analyst upgrades, downgrades and initiations on Monday included Apple, Carnival, Generac, Lyft, Six Flags, Square, Tecnoglass, Yum! Brands, Western Digital and Zoetis.
The top analyst upgrades, downgrades and initiations seen on Thursday included American Eagle Outfitters, Atlassian, Match, NextEra Energy, Nordstom, Office Depot, Roku, Stamps.com and Tanger Factory...
The top analyst upgrades, downgrades and initiations seen on Tuesday included Alcoa, Apple, Autodesk, BB&T, Bed Bath & Beyond, Camping World, Nvidia, Vertex Pharmaceuticals and Voya Financial.
Arena Pharmaceuticals shares jumped early on Thursday after the company announced a new global license agreement with United Therapeutics.
MannKind shares are continuing their rally from Tuesday when it was announced that United Therapeutics was licensing MannKind a dry powder formulation of treprostinil, the active ingredient in...
SteadyMed saw its shares skyrocket early on Monday after the company announced that it would be acquired by United Therapeutic.
The top analyst upgrades, downgrades and other research calls from Tuesday include AngioDynamics, Commercial Metals, Eldorado Resorts, Gamestop, Marvell Technology, Spotify and U.S. Steel.
The top analyst upgrades, downgrades and other research calls from Wednesday include Callaway Golf, Capital One, Sarepta Therapeutics, Tesla, UnitedHealth and Wayfair.
The top analyst upgrades, downgrades and initiations include ConocoPhillips, Goodyear Tire, Humana, Lululemon Athletica and Range Resources.